NCT lookup

Inclusion Criteria:

All patients must meet the following inclusion criteria during the identification period:

* Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.
* ≥ 18 years old at the time of enrollment
* Written informed consent must be obtained prior to any data collection
* Willing to participate in Quality of Life post treatment date collection for 1 year

Exclusion Criteria:

Patients must not meet the following exclusion criterion during the identification period:

\- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan

• Konstanz, Baden-Wurttemberg, Germany
• Stuttgart, Baden-Wurttemberg, Germany
• Munich, Bavaria, Germany
• Regensburg, Bavaria, Germany
• Würzburg, Bavaria, Germany
• Cottbus, Brandenburg, Germany
• Frankfurt (Oder), Brandenburg, Germany
• Ludwigshafen, Germany, Germany
• Marburg, Hesse, Germany
• Cologne, North Rhine-Westphalia, Germany
• Dresden, Saxony, Germany
• Leipzig, Saxony, Germany
• Halle, Saxony-Anhalt, Germany
• Jena, Thuringia, Germany
• Aachen, Germany
• Augsburg, Germany
• Berlin, Germany
• Berlin, Germany
• Berlin, Germany
• Bielefeld, Germany
• Bonn, Germany
• Braunschweig, Germany
• Chemnitz, Germany
• Dortmund, Germany
• Dortmund, Germany
• Erfurt, Germany
• Erlangen, Germany
• Essen, Germany
• Fulda, Germany
• Herford, Germany
• + 8 more on CT.gov